

CERTIFICATE OF ANALYSIS – TECHNICAL DATA SHEET

Product name iC3b, C3dg, C3d, Human, clone C3-12.2

Catalog number HM2395-100UG

Lot number - Expiry date

Volume 1 ml Amount 100 μg

Formulation 0.2 μm filtered in PBS+0.1%BSA+0.02%NaN3 Concentration 100 μg/ml

Host Species Mouse IgG1 Conjugate None


Endotoxin N.A. Purification Protein G


Storage 4°C

Application notes

	IHC-F	IHC-P	IF	FC	FS	IA	IP	W
Reference #								1
Yes						•		•
No								
N.D.	•	•	•	•	•		•	

N.D.= Not Determined; IHC = Immuno histochemistry; F = Frozen sections; P = Paraffin sections; IF = Immuno Fluorescence; FC = Flow Cytometry; FS = Functional Studies; IA = Immuno Assays; IP = Immuno Precipitation; W = Western blot





W: western blot of HM2395 under non-reduced and reduced conditions. Lane 1 to 12 are marker, C3, C3a, C3a-des-arg, marker, C3b, iC3b, C3c, c3d, marker, preserved plasma, zymosan activated plasma.

Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.

- IA: antibody C3-12.2 was used in a direct ELISA.
- W: the antibody can be used for reduced and non-reduced samples. (Ref.1)

General Information

Description

The antibody clone C3-12.2 recognize complement iC3b, C3dg, and C3d. The recognition domain is determined to CUB-TED. The antibody blocks C3 activation by AP C3-convertase. The complement system plays important roles in both innate and adaptive immune response and can produce an inflammatory and protective reaction to challenges from pathogens before an adaptive response can occur. It consists of a complex family of proteins and receptors which are found in the circulation, in tissues and other body-fluids. There are three pathways of complement activation. The classical pathway is initiated by Immune complexes; the lectin pathway by surface bound lectins; and the AP by all the surfaces that are not specifically protected against it. Each generates a C3 convertase, a serine protease that cleaves the central complement protein C3, and generates the major cleavage fragment C3b. The C3 and C5 convertases are enzymatic complexes that initiate and amplify the activity of the complement pathways and ultimately generate the cytolytic MAC. The synthesis of C3 is tissue-specific and is modulated in response to a variety of stimulatory agents. After cleavage by C3 convertase the anaphylotoxin C3a and activating C3b are formed. When bound to the cell surface C3b forms the start of the terminal pathway of complement by initiating the formation of the C5 convertase. C3 has a molecular weight of app. 185kDa and is the most abundant protein of the complement system with serum protein levels of about 1.3 mg/ml. C3 is primarily produced by the liver but is also generated in macrophages, neutrophils, endothelial and epithelial cells. Due to the high levels in circulation with low biological reactivity, C3 is able to act in a fast and potent way when danger by e.g. pathogens is encountered. Defects in C3 can be unfavorable to the host leading to

Version: 06-2020

recurrent infections or auto-immune diseases. Although rare, C3 deficiency has been reported. These patients suffer from recurrent infections of eg S.pneumoniae or N.meningitidis due to lack of opsonization, but also impaired DC and Treg development. Polymorphism in C3 has been associated with AMD and aHUS. Besides clearance of pathogens, C3 is also important in removal of circulating immune-complexes by assisting the phagocytic capacity of macrophages. Malfunction of this system can lead to development of auto-immune disease and complement deposition in tissues.

Immunogen Mixture of the human activated C3 fragments, C3b, iC3b, and C3dg, emulsified in complete Freund's adjuvant.

Subsequently, mice were boosted three times at 2-week intervals with the same amount of C3 fragments in incomplete

adjuvant.

Aliases Complement component C3b, iC3b, C3c

References Hildago, M et al; Functional and structural characterization of four mouse monoclonal antibodies to complement C3

with potential therapeutic and diagnostic applications. Eur J Immunol 2017, 47:504

Storage&stability Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year.

PrecautionsFor research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent

infringements that might result from the use or derivation of this product.

We hereby certify that the above-stated information is correct and that this product has been successfully tested by the Quality Control Department. This product was released for sale according to the existing specifications. This document has been produced electronically and is valid without a signature.

Approved by Manager of QC Date Brenda Teunissen 26/06/2020

Do you have any questions or comments regarding this product? Please contact us via support@hycultbiotech.com.

Version: 06-2020